Payment overview · 2025
General Payments
$294.47
12 reported records · 9 companies
Healthcare provider profile · identity verified
Brijesh Goyal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AMITYVILLE, NY · NPI 1245247402
Verified facts
What the public records show
CMS Open Payments records show Brijesh Goyal, M.D. received $294.47 in general payments during 2025 across 12 reported records.
Inspire Medical Systems, Inc. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $52.37 | 17.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.22 | 15.7% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $38.43 | 13.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.64 | 10.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.01 | 9.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.72 | 9.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.32 | 9.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.82 | 8.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.94 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.47 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 553 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 517 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 389 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 54 |
| Eliquis | Apixaban | 284 | 45 |
| Gabapentin | Gabapentin | 240 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 41 |
| Potassium Chloride | Potassium Chloride | 224 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 30 |
| Losartan Potassium | Losartan Potassium | 183 | 35 |
| Lisinopril | Lisinopril | 175 | 23 |
| Simvastatin | Simvastatin | 173 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 18 |
| Omeprazole | Omeprazole | 122 | 23 |
| Donepezil Hcl | Donepezil Hcl | 107 | 22 |
| Ezetimibe | Ezetimibe | 105 | 13 |
| Memantine Hcl | Memantine Hcl | 94 | 16 |
| Famotidine | Famotidine | 91 | 22 |
| Finasteride | Finasteride | 88 | 17 |
| Mirtazapine | Mirtazapine | 86 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 28 |
| Metformin Hcl | Metformin Hcl | 75 | 13 |
| Montelukast Sodium | Montelukast Sodium | 71 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 11 |
| Torsemide | Torsemide | 67 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Carvedilol | Carvedilol | 55 | 13 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 27 |
| Tramadol Hcl | Tramadol Hcl | 52 | 18 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Irbesartan | Irbesartan | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Baclofen | Baclofen | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 31 |
| Loperamide | Loperamide Hcl | 33 | 15 |
| Nystatin | Nystatin | 33 | 19 |
| Potassium Citrate Er | Potassium Citrate | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 14 |
| Azithromycin | Azithromycin | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Prednisone | Prednisone | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Klor-Con 8 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Dofetilide | Dofetilide | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Methazolamide | Methazolamide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.47 · 12 records | Inspire Medical Systems, Inc. | Auvelity, FARXIGA, GEMTESA, IBSRELA, INSPIRE, PERCEPT PC BRAINSENSE, REXULTI, TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error